Livzon Mabpharm Leads $36 Million Funding of Epirus, a US Biosimilar Co.

Livzon Mabpharm of China led a $36 million Series B funding round for Epirus Biopharma, a Boston-based company developing biosimilars. Simultaneously, Epirus announced a reverse-merger with Zalicus, a company with a portfolio of innovative pain medication candidates. After the transaction, Epirus will own about 86% of the merged company. More details.... Stock Symbol: (NSDQ: ZLCS) Share this with colleagues: // //